Optimised dosage of diaminophenothiazines in populations

Patent metadata

Field	Value
Publication number	US-12263175-B2
Application number	US-202217961961-A
Country	US
Kind code	B2
Filing date	Oct 7, 2022
Priority date	Jul 26, 2018
Publication date	Apr 1, 2025
Grant date	Apr 1, 2025

Abstract

The invention provides novel dosing regimens for Leuco-Methylthioninium (LMT) compounds which maximise the proportion of subjects in which the MT concentration will exceed concentrations in which therapeutic efficacy in relation to treatment of neurodegenerative disorders such as Alzheimer's disease and rontotemporal dementias can be achieved, while maintaining a desirable clinical profile. Also provided are LMT-containing dosage units and other compositions.

First claim

The invention claimed is:

1. A method of therapeutic treatment of a neurodegenerative disorder of protein aggregation in a human subject,
which method comprises orally administering to said subject a methylthioninium (MT)-containing compound,
wherein said administration provides a total daily dose of between 20.5 and 60 mg of MT to the subject per day, optionally split into 2 or more doses,
wherein the MT-containing compound is LMTM:

wherein said neurodegenerative disorder is behavioral-variant frontotemporal dementia (bvFTD), and
wherein the therapeutic treatment is not combined with an acetylcholinesterase inhibitor or an N-methyl-D-aspartate receptor antagonist.

2. The method as claimed in claim 1 , wherein the total daily dose is between 20.5 and 40 mg.

3. The method as claimed in claim 2 , wherein the total daily dose is 21 to 40 mg.

4. The method as claimed in claim 3 , wherein the total daily dose is 21 to 32 mg.

5. The method as claimed in claim 3 , wherein the total daily dose is or 24 to 32 mg.

6. The method as claimed in claim 2 , wherein the total daily dose is about 30 mg.

7. The method as claimed in claim 1 , wherein the total daily dose of the MT-containing compound is administered as a split dose twice a day or three times a day.

8. The method as claimed in claim 7 , wherein the total daily dose of the MT-containing compound is administered as a split dose twice a day.

9. The method as claimed in claim 7 , wherein the total daily dose of the MT-containing compound is administered as a split dose three times a day.

10. The method as claimed in claim 1 , wherein the subject
has not historically received treatment with an acetylcholinesterase inhibitor or an N-methyl-D-aspartate receptor antagonist.

11. The method as claimed in claim 1 , wherein the treatment is part of a treatment regimen which comprises:
(i) orally administering to said subject the MT-containing compound for a first period of time, wherein said administration provides a total daily dose of between 1 and 10 mg of MT to the subject per day;
(ii) orally administering to said subject the MT-containing compound for a further period of time, wherein said administration provides a total daily dose of between 20.5 and 60 mg of MT to the subject per day.

12. The method as claimed in claim 11 , wherein the administration of step (i) provides a total daily dose of 8 mg of MT to the subject per day.

13. The method as claimed in claim 11 , wherein the administration of step (ii) provides a total daily dose of between 20.5 and 50 mg of MT to the subject per day.

14. The method as claimed in claim 13 , wherein the administration of step (ii) provides a total daily dose of between 20.5 and 40 mg of MT to the subject per day.

15. The method as claimed in claim 1 , wherein the MT-containing compound is administered once per day.

16. The method as claimed in claim 1 , wherein the subject has historically received treatment with an acetylcholinesterase inhibitor or an N-methyl-D-aspartate receptor antagonist, but ceased that treatment at least 1, 2, 3, 4, 5, 6, 7, or 8 weeks prior to treatment with the MT-containing compound.

17. The method as claimed in claim 16 , wherein the subject has historically received treatment with an acetylcholinesterase inhibitor or an N-methyl-D-aspartate receptor antagonist, but ceased that treatment at least 1, 2, 3, 4, 5, or 6 months prior to treatment with the MT-containing compound.

18. The method as claimed in claim 1 , wherein the subject is selected as one who is receiving treatment with an acetylcholinesterase inhibitor or an N-methyl-D-aspartate receptor, wherein said treatment with the acetylcholinesterase inhibitor and/or N-methyl-D-aspartate receptor antagonist is discontinued prior to treatment with the MT-containing compound.

19. The method as claimed in claim 1 , wherein administration provides a total daily dose of between 20.5 and 60 mg of MT to the subject per day, split into 2 or more doses.

20. The method as claimed in claim 1 , wherein the MT-containing compound is administered in a powder, capsule, pill, tablet, caplet, or gelcap.

Assignees

• Wista Lab Ltd

Inventors

• Wischik Claude Michel
• Schelter Bjorn Olaf
• Shiells Helen Christine

Classifications

• A61K31/13

  Amines {(A61K31/04 takes precedence)} · CPC title

• A61K9/48

  Preparations in capsules, e.g. of gelatin, of chocolate {(A61K9/0004 takes precedence; bite capsules A61K9/0056)} · CPC title

• A61K9/20

  Pills, tablets, {discs, rods (A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095)} · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title